- Case-Based Roundtable
- General Dermatology
- Eczema
- Chronic Hand Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
- Buy-and-Bill
News
Article
Exploring the 2025 Revolutionizing Atopic Dermatitis (RAD) Annual Meeting Agenda
Author(s):
Key Takeaways
- The RAD 2025 conference will cover a wide range of AD topics, including JAK inhibitors, psychosocial impacts, and pediatric AD.
- Esteemed speakers will provide insights into novel therapeutic approaches and management strategies for AD.
Get a glimpse of the cutting-edge atopic dermatitis research, breakthroughs, and insights to be presented at the 7th RAD Annual Meeting, June 6-7, 2025.
Image Credit: © Gennady Danilkin - stock.adobe.com
The Revolutionizing Atopic Dermatitis (RAD) Annual Meeting has unveiled its comprehensive agenda for the upcoming 7th annual conference, scheduled for June 6-7, 2025, in Nashville, Tennessee. This year's event promises an engaging lineup of sessions and esteemed speakers, continuing to advance knowledge and fostering innovation in the field of atopic dermatitis (AD).
Click here to view the full agenda and learn more about registration and attendance.
Agenda Highlights
The 2-day conference is structured to cover a wide array of topics pertinent to AD, featuring sessions led by numerous experts in dermatology. Below is an overview of the scheduled sessions:
Friday, June 6
- The Psychosocial Burden of AD
- JAK Inhibitors in AD
- Complex Cases: AD & Hair Loss
- Recent Approvals in AD Therapy
- Topicals and Biologics - When and Why
- Managing Itch
Saturday, June 7
- Pediatric AD: Part 1 & 2
- Pediatric AD: Patient, Provider, Caregiver Connection
- Assessing the Evidence for OX40-OX40L Axis Inhibition for the Treatment of Atopic Dermatitis
- Medical Crossfire: IL-31 and IL-13
- Dose Flexibility in Adult AD
- Chronic Hand Eczema
The meeting will also feature late-breaking research presents and poster/abstract submissions.
Notable Speakers
The RAD 2025 conference boasts a distinguished roster of speakers, each bringing a wealth of expertise and insight into various facets of AD:
- Christopher Bunick, MD, PhD: Bunick will explore the emerging role of OX40-OX40L axis inhibition in AD treatment, analyzing the latest evidence and its potential impact on patient care. His session will provide key insights into this novel therapeutic approach.
- Mona Shahriari, MD: Leading the session on the psychosocial burden of AD, Shahriari will explore the emotional and psychological challenges faced by patients, emphasizing the importance of holistic care approaches.
- Raj Chovatiya, MD, PhD, MSCI: Chovatiya will delve into the role of Janus kinase inhibitors in AD treatment and discuss the strategic use of topicals and biologics, providing attendees with a comprehensive understanding of current therapeutic options.
- Tiffany T. Mayo, MD: Addressing complex cases involving AD and hair loss, Mayo will shed light on the intersection of these conditions and offer guidance on effective management strategies.
- Jonathan I. Silverberg, MD, PhD, MPH: With sessions focusing on recent approvals in AD therapy and managing itch, Silverberg will provide updates on the latest treatment advancements and strategies for alleviating pruritus.
- Peter Lio, MD: Lio will lead discussions on the unique challenges of treating pediatric AD, emphasizing the importance of patient-provider-caregiver collaboration. His session will address both clinical strategies and the psychosocial aspects of managing AD in younger populations.
- Jiade Yu, MD, MS: As an expert on chronic hand eczema, Yu will highlight the challenges associated with this condition in the context of AD, providing best practices for diagnosis and treatment.
Dermatology Times is proud to have been a long-standing partner of RAD, providing in-depth coverage of its 2024, 2023, and 2022 in-person and virtual events. Following the acquisition of RAD by MJH Life Sciences—Dermatology Times’ parent company—in November 2024, RAD is now part of our family of educational resources.1
As RAD enters its next chapter under the Physicians’ Education Resource umbrella, Dermatology Times looks forward to continuing the tradition of delivering exclusive coverage of the meeting’s groundbreaking sessions and expert discussions. Leading up to this year's event, we will be previewing key sessions with insights from featured speakers, and our team will be on-site in Music City to bring real-time coverage, expert pearls, and updates on the most important innovations in AD.
Stay tuned for updates as more speakers and late-breaking research presentations are announced. For registration details and additional information, visit the official RAD conference website.
Reference
- MJH Life Sciences acquires Revolutionizing Atopic Dermatitis (RAD) Annual Meeting; expands leadership in dermatology education. News release. Accessed April 2, 2025. https://www.globenewswire.com/news-release/2024/11/18/2982960/0/en/MJH-Life-Sciences-acquires-Revolutionizing-Atopic-Dermatitis-RAD-Annual-Meeting-expands-leadership-in-dermatology-education.html
